Neimeth International Pharmaceuticals Plc (NGX:NEIMETH)
Nigeria
· Delayed Price · Currency is NGN 3.340
0.00 (0.00%)
At close: Jun 5, 2025
NGX:NEIMETH Income Statement
Financials in millions NGN. Fiscal year is January - December.
Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2016 - 2020 |
| Revenue | 5,043 | 4,485 | 2,210 | 2,919 | 2,703 | 3,047 | Upgrade
|
| Revenue Growth (YoY) | 111.09% | 102.98% | -24.31% | 8.01% | -11.29% | 7.31% | Upgrade
|
| Cost of Revenue | 2,974 | 2,550 | 1,500 | 1,886 | 1,629 | 1,622 | Upgrade
|
| Gross Profit | 2,069 | 1,936 | 709.15 | 1,033 | 1,074 | 1,425 | Upgrade
|
| Selling, General & Admin | 1,300 | 1,286 | 1,636 | 1,204 | 1,125 | 1,074 | Upgrade
|
| Other Operating Expenses | -1,247 | -1,183 | -1,225 | -157.95 | -26.15 | -197.17 | Upgrade
|
| Operating Expenses | 53.13 | 103.7 | 410.42 | 1,046 | 1,099 | 876.42 | Upgrade
|
| Operating Income | 2,016 | 1,832 | 298.73 | -12.39 | -24.8 | 548.74 | Upgrade
|
| Interest Expense | -1,075 | -873.32 | -667.95 | -300 | -181.77 | -188.22 | Upgrade
|
| Interest & Investment Income | 287.13 | 231.39 | 129.23 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -2,048 | -2,048 | -1,451 | 1.94 | 96.89 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -819.93 | -858.03 | -1,691 | -310.45 | -109.67 | 360.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.6 | 3.6 | 0.97 | - | - | 4.86 | Upgrade
|
| Pretax Income | -816.33 | -854.43 | -1,690 | -310.44 | -109.66 | 365.28 | Upgrade
|
| Income Tax Expense | 30.9 | 30.9 | 107.88 | 14.6 | - | 94.71 | Upgrade
|
| Net Income | -847.23 | -885.33 | -1,798 | -325.04 | -109.66 | 270.58 | Upgrade
|
| Net Income to Common | -847.23 | -885.33 | -1,798 | -325.04 | -109.66 | 270.58 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 27.34% | Upgrade
|
| Shares Outstanding (Basic) | 4,273 | 4,273 | 4,273 | 1,899 | 1,899 | 1,899 | Upgrade
|
| Shares Outstanding (Diluted) | 4,273 | 4,273 | 4,273 | 1,899 | 1,899 | 1,899 | Upgrade
|
| Shares Change (YoY) | 2.79% | - | 125.00% | - | - | - | Upgrade
|
| EPS (Basic) | -0.20 | -0.21 | -0.42 | -0.17 | -0.06 | 0.14 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.21 | -0.42 | -0.17 | -0.06 | 0.14 | Upgrade
|
| EPS Growth | - | - | - | - | - | 27.34% | Upgrade
|
| Free Cash Flow | 199.18 | -306.71 | -1,710 | -1,137 | -1,205 | 1.96 | Upgrade
|
| Free Cash Flow Per Share | 0.05 | -0.07 | -0.40 | -0.60 | -0.63 | 0.00 | Upgrade
|
| Dividend Per Share | - | - | - | - | - | 0.070 | Upgrade
|
| Dividend Growth | - | - | - | - | - | 7.69% | Upgrade
|
| Gross Margin | 41.02% | 43.16% | 32.09% | 35.39% | 39.74% | 46.78% | Upgrade
|
| Operating Margin | 39.97% | 40.84% | 13.52% | -0.43% | -0.92% | 18.01% | Upgrade
|
| Profit Margin | -16.80% | -19.74% | -81.35% | -11.13% | -4.06% | 8.88% | Upgrade
|
| Free Cash Flow Margin | 3.95% | -6.84% | -77.37% | -38.95% | -44.57% | 0.06% | Upgrade
|
| EBITDA | 2,147 | 1,962 | 424.82 | 96.02 | 94.78 | 639.06 | Upgrade
|
| EBITDA Margin | 42.56% | 43.74% | 19.23% | 3.29% | 3.51% | 20.98% | Upgrade
|
| D&A For EBITDA | 130.75 | 129.99 | 126.09 | 108.41 | 119.57 | 90.32 | Upgrade
|
| EBIT | 2,016 | 1,832 | 298.73 | -12.39 | -24.8 | 548.74 | Upgrade
|
| EBIT Margin | 39.97% | 40.84% | 13.52% | -0.42% | -0.92% | 18.01% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 25.93% | Upgrade
|
| Advertising Expenses | - | 192.93 | 363.67 | - | 188.49 | 224.46 | Upgrade
|
Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.